UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi99-vi105

2013

Volltextzugriff (PDF)

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2021-07, Vol.32 (7), p.839-853

2021

Volltextzugriff (PDF)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Annals of oncology, 2019-08, Vol.30 (8), p.1321-1328

2019

Volltextzugriff (PDF)

EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer

Annals of oncology, 2019-08, Vol.30 (8), p.1190-1192

2019

Volltextzugriff (PDF)

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v116-v119

2010

Volltextzugriff (PDF)

Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy Reveal In Situ Linkage Errors

ACS nano, 2021-07, Vol.15 (7), p.12161-12170

2021

Volltextzugriff (PDF)

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Annals of oncology, 2016-02, Vol.27 (2), p.281-286

2016

Volltextzugriff (PDF)

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Annals of oncology, 2022-02, Vol.33 (2), p.181-192

2022

Volltextzugriff (PDF)

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study

Lung cancer (Amsterdam, Netherlands), 2019-04, Vol.130, p.149-155

2019

Volltextzugriff (PDF)

Multianalyte lateral flow immunoassay for simultaneous detection of protein-based inflammation biomarkers and pathogen DNA

Sensors and actuators. B, Chemical, 2022-03, Vol.355, p.131283, Article 131283

2022

Volltextzugriff (PDF)

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Annals of oncology, 2020-04, Vol.31 (4), p.495-500

2020

Volltextzugriff (PDF)

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study

Lung cancer (Amsterdam, Netherlands), 2024-01, Vol.187, p.107427-107427, Article 107427

2024

Volltextzugriff (PDF)

The search for improved systemic therapy of non-small cell lung cancer—What are today's options?

Lung cancer (Amsterdam, Netherlands), 2011-06, Vol.72 (3), p.265-270

Früh, M

2011

Volltextzugriff (PDF)

Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

Radiotherapy and oncology, 2020-08, Vol.149, p.84-88

2020

Volltextzugriff (PDF)

Analyzing siRNA Concentration, Complexation and Stability in Cationic Dendriplexes by Stem-Loop Reverse Transcription-qPCR

Pharmaceutics, 2022-06, Vol.14 (7), p.1348

2022

Volltextzugriff (PDF)

Covalent Cargo Loading to Molecular Shuttles via Copper-free “Click Chemistry”

Biomacromolecules, 2012-12, Vol.13 (12), p.3908-3911

2012

Volltextzugriff (PDF)

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma

Lung cancer (Amsterdam, Netherlands), 2015-01, Vol.87 (1), p.85-87

2015

Volltextzugriff (PDF)

Rapid Detection of Pathogens in Wound Exudate via Nucleic Acid Lateral Flow Immunoassay

Biosensors (Basel), 2021-03, Vol.11 (3), p.74

2021

Volltextzugriff (PDF)

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non‐small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices

European journal of cancer care, 2017-11, Vol.26 (6), p.e12721-n/a

2017

Volltextzugriff (PDF)

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

Lung cancer (Amsterdam, Netherlands), 2020-08, Vol.146, p.6-11

2020

Volltextzugriff (PDF)

Nanoshuttles propelled by motor proteins sequentially assemble molecular cargo in a microfluidic device

Lab on a chip, 2014-10, Vol.14 (19), p.3729-3738

2014

Volltextzugriff (PDF)

The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action

Current drug targets, 2010-01, Vol.11 (1), p.37-47

2010

Volltextzugriff (PDF)

Eliminating viscosity bias in lateral flow tests

Microsystems & nanoengineering, 2021-09, Vol.7 (1), p.72-72, Article 72

2021

Volltextzugriff (PDF)

VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Annals of oncology, 2021-07, Vol.32 (7), p.942-944

2021

Volltextzugriff (PDF)

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.306-313

2014

Volltextzugriff (PDF)

1 – 25 von 585

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(480)
Mit Volltextzugriff
(508)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(323)
Life Sciences & Biomedicine
(240)
Humans
(162)
Animals
(90)
Female
(74)
Physical Sciences
(73)
Male
(60)
Biological And Medical Sciences
(53)
Oncology
(46)
Adult
(43)
Mice
(42)
Microbiology
(42)
Middle Aged
(42)
Virology
(40)
Immunology
(33)
Science & Technology - Other Topics
(33)
Isotopes
(30)
Medical Sciences
(30)
Stable Isotopes
(30)
Aged
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy Reveal In Situ Linkage Errors

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study

Multianalyte lateral flow immunoassay for simultaneous detection of protein-based inflammation biomarkers and pathogen DNA

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study

The search for improved systemic therapy of non-small cell lung cancer—What are today's options?

Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

Analyzing siRNA Concentration, Complexation and Stability in Cationic Dendriplexes by Stem-Loop Reverse Transcription-qPCR

Covalent Cargo Loading to Molecular Shuttles via Copper-free “Click Chemistry”

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma

Rapid Detection of Pathogens in Wound Exudate via Nucleic Acid Lateral Flow Immunoassay

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non‐small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

Nanoshuttles propelled by motor proteins sequentially assemble molecular cargo in a microfluidic device

The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action

Eliminating viscosity bias in lateral flow tests

VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Suchergebnisse filtern